Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Gritstone Bio Inc (GRTS)

Gritstone Bio Inc (GRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street - shutterstock_2269106477
Stocks Tread Water Before the Open as Investors Await Key U.S. GDP Data, Nike Earnings on Tap Barchart - Thu Sep 28, 2023

December S&P 500 futures (ESZ23) are up +0.04%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.05% this morning as market participants geared up for a flurry of U.S. economic data while also...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NEE : 76.38 (-0.01%)
ZION : 58.67 (-0.88%)
PAYX : 140.43 (-0.94%)
NKE : 73.91 (-1.31%)
ACN : 350.90 (-0.54%)
JBL : 127.45 (-0.65%)
KMX : 74.75 (-3.05%)
RYA.I.DX : 18.500 (-1.25%)
MU : 97.83 (+0.33%)
PTON : 7.50 (-1.06%)
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors Globe Newswire - Wed Aug 10, 2022

-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Tue Jul 26, 2022

EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022 Globe Newswire - Thu Jul 21, 2022

Conference call to occur at 4:30pm ET on August 4...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications Globe Newswire - Fri Jun 10, 2022

-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Wed Jun 8, 2022

EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
Gritstone Earns 2022 Great Place to Work Certification™ Globe Newswire - Thu Jun 2, 2022

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
Gritstone to Participate in H.C. Wainwright Global Investment Conference Globe Newswire - Tue May 17, 2022

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.0322 (-31.78%)
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Fri May 6, 2022

-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data...

GRTS : 0.0322 (-31.78%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Wed Apr 27, 2022

EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next...

GRTS : 0.0322 (-31.78%)

Barchart Exclusives

After Underperforming in 2024, is Mega-Cap Microsoft Stock Still a Buy? Barchart - 25 minutes ago
MSFT has underperformed the markets this year, but analysts still like the stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot